STAAR Surgical (STAA) shares are soaring 5.05% in Thursday's intraday trading following the company's strong third-quarter results and a statement from major shareholder Yunqi Capital opposing a proposed sale to Alcon.

The eye care technology company's impressive Q3 performance has caught the attention of investors and analysts alike. Yunqi Capital, a significant stakeholder in STAAR Surgical, expressed its approval of the robust financial results. However, the investment firm also reiterated its stance against the proposed sale to Alcon, suggesting that the deal may not be in the best interest of shareholders given STAAR's strong independent performance.

This development has sparked renewed interest in STAAR Surgical's stock, as investors weigh the company's standalone potential against the proposed acquisition. The market's positive reaction indicates that many shareholders may share Yunqi Capital's view, preferring to see STAAR continue as an independent entity rather than being absorbed by Alcon. As the situation unfolds, all eyes will be on STAAR Surgical's management and their response to this latest shareholder feedback.